111 related articles for article (PubMed ID: 8441030)
1. Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside.
Moore RB; Chapman JD; Mercer JR; Mannan RH; Wiebe LI; McEwan AJ; McPhee MS
J Nucl Med; 1993 Mar; 34(3):405-11. PubMed ID: 8441030
[TBL] [Abstract][Full Text] [Related]
2. Marking hypoxia in rat prostate carcinomas with beta-D-[125I]azomycin galactopyranoside and.
Iyer RV; Haynes PT; Schneider RF; Movsas B; Chapman JD
J Nucl Med; 2001 Feb; 42(2):337-44. PubMed ID: 11216534
[TBL] [Abstract][Full Text] [Related]
3. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
[TBL] [Abstract][Full Text] [Related]
4. Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors.
Chapman JD; McPhee MS; Walz N; Chetner MP; Stobbe CC; Soderlind K; Arnfield M; Meeker BE; Trimble L; Allen PS
J Natl Cancer Inst; 1991 Nov; 83(22):1650-9. PubMed ID: 1749018
[TBL] [Abstract][Full Text] [Related]
5. Imaging tumor hypoxia and tumor perfusion.
Groshar D; McEwan AJ; Parliament MB; Urtasun RC; Golberg LE; Hoskinson M; Mercer JR; Mannan RH; Wiebe LI; Chapman JD
J Nucl Med; 1993 Jun; 34(6):885-8. PubMed ID: 8389842
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole.
Gonzalez S; Arnfield MR; Meeker BE; Tulip J; Lakey WH; Chapman JD; McPhee MS
Cancer Res; 1986 Jun; 46(6):2858-62. PubMed ID: 3698010
[TBL] [Abstract][Full Text] [Related]
7. Autoradiographic imaging of cerebral ischaemia using a combination of blood flow and hypoxic markers in an animal model.
Lythgoe MF; Williams SR; Wiebe LI; McEwan AJ; Gordon I
Eur J Nucl Med; 1997 Jan; 24(1):16-20. PubMed ID: 9044870
[TBL] [Abstract][Full Text] [Related]
8. Second generation hypoxia imaging agents.
Biskupiak JE; Krohn KA
J Nucl Med; 1993 Mar; 34(3):411-3. PubMed ID: 8441031
[No Abstract] [Full Text] [Related]
9. Non-invasive monitoring of photodynamic therapy with 99technetium HMPAO scintigraphy.
Moore RB; Chapman JD; Mokrzanowski AD; Arnfield MR; McPhee MS; McEwan AJ
Br J Cancer; 1992 Apr; 65(4):491-7. PubMed ID: 1562457
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study.
Parliament MB; Chapman JD; Urtasun RC; McEwan AJ; Golberg L; Mercer JR; Mannan RH; Wiebe LI
Br J Cancer; 1992 Jan; 65(1):90-5. PubMed ID: 1310253
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry estimations for 123I-IAZA in healthy volunteers.
Stypinski D; McQuarrie SA; Wiebe LI; Tam YK; Mercer JR; McEwan AJ
J Nucl Med; 2001 Sep; 42(9):1418-23. PubMed ID: 11535735
[TBL] [Abstract][Full Text] [Related]
12. Fractionated versus standard continuous light delivery in interstitial photodynamic therapy of dunning prostate carcinomas.
Xiao Z; Halls S; Dickey D; Tulip J; Moore RB
Clin Cancer Res; 2007 Dec; 13(24):7496-505. PubMed ID: 18094434
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.
Busch TM; Wileyto EP; Emanuele MJ; Del Piero F; Marconato L; Glatstein E; Koch CJ
Cancer Res; 2002 Dec; 62(24):7273-9. PubMed ID: 12499269
[TBL] [Abstract][Full Text] [Related]
14. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
Busch TM; Hahn SM; Evans SM; Koch CJ
Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
[TBL] [Abstract][Full Text] [Related]
15. Preclinical assessment of hypoxic marker specificity and sensitivity.
Iyer RV; Engelhardt EL; Stobbe CC; Schneider RF; Chapman JD
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):741-5. PubMed ID: 9845088
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of 123I-IAZA in healthy volunteers.
Stypinski D; Wiebe LI; McEwan AJ; Schmidt RP; Tam YK; Mercer JR
Nucl Med Commun; 1999 Jun; 20(6):559-67. PubMed ID: 10451869
[TBL] [Abstract][Full Text] [Related]
17. Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside.
Urtasun RC; Parliament MB; McEwan AJ; Mercer JR; Mannan RH; Wiebe LI; Morin C; Chapman JD
Br J Cancer Suppl; 1996 Jul; 27():S209-12. PubMed ID: 8763882
[TBL] [Abstract][Full Text] [Related]
18. Interstitial Doppler optical coherence tomography as a local tumor necrosis predictor in photodynamic therapy of prostatic carcinoma: an in vivo study.
Standish BA; Lee KK; Jin X; Mariampillai A; Munce NR; Wood MF; Wilson BC; Vitkin IA; Yang VX
Cancer Res; 2008 Dec; 68(23):9987-95. PubMed ID: 19047181
[TBL] [Abstract][Full Text] [Related]
19. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia.
Mannan RH; Somayaji VV; Lee J; Mercer JR; Chapman JD; Wiebe LI
J Nucl Med; 1991 Sep; 32(9):1764-70. PubMed ID: 1880579
[TBL] [Abstract][Full Text] [Related]
20. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings.
Zhao D; Ran S; Constantinescu A; Hahn EW; Mason RP
Neoplasia; 2003; 5(4):308-18. PubMed ID: 14511402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
